SCHEMBL2915435

SCHEMBL2915435

O=C(O)Cc1cccc(N2CCC3(CC2)C(=O)N(CC2CCC2)C(=O)N3CCc2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 2/20 0.38
KCNH2 Q12809 3/20 0.37
ITGB3 P05106 2/20 0.37
ITGA2B P08514 2/20 0.37
HRH1 P35367 1/20 0.37
CCR3 P51677 1/20 0.37
TACR1 P25103 1/20 0.37
EBP Q15125 3/20 0.36
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 2/20 0.35
GCGR P47871 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
TSHR P16473 1/20 0.35
NFKB1 P19838 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2910510 0.98 SIGMAR1 (0.38) SIGMAR1KCNH2ITGB3ITGA2BHRH1
SCHEMBL2909717 0.92 ITGB3 (0.41) SIGMAR1KCNH2ITGB3ITGA2BHRH1
SCHEMBL2914958 0.91 ITGB3 (0.41) SIGMAR1KCNH2ITGB3ITGA2BHRH1
SCHEMBL2909327 0.90 OPRM1 (0.36) SIGMAR1KCNH2TACR1EBPKMT2A
SCHEMBL13849471 0.90 FFAR4 (0.39) KCNH2ITGB3ITGA2BHRH1CCR3
SCHEMBL2912462 0.88 HRH1 (0.41) SIGMAR1KCNH2ITGB3ITGA2BHRH1
SCHEMBL2917453 0.88 FFAR4 (0.42) KCNH2ITGB3ITGA2BHRH1CCR3
SCHEMBL13849472 0.85 ITGB3 (0.37) KCNH2ITGB3ITGA2BHRH1CCR3
SCHEMBL2912597 0.84 FFAR4 (0.43) KCNH2ITGB3ITGA2BHRH1CCR3
SCHEMBL2914627 0.84 TACR1 (0.37) SIGMAR1KCNH2ITGB3ITGA2BHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979355-B1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2010-08-18 EP claimed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US claimed
EP-1979355-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2008-10-15 EP claimed
WO-2007087448-A1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2007-08-02 WO claimed
EP-1979355-B1 SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2010-08-18 EP disclosed
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS IRM LLC (BM) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137610-A1 SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS PPARD, PPARG, PPARA SIGMAR1 1402/4885KCNH2 3975/4885ITGB3 2615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.